Apeloa Pharmaceutical and Hangzhou Apeloa Medicine Research Institute have described new N-(benzoyl)-phenylalanine compounds acting as integrin alpha4beta7 (LPAM-1) antagonists reported to be useful for the treatment of inflammatory bowel disease.

Guangdong Newopp Biopharmaceuticals has disclosed Son of sevenless homolog 1 (SOS1)/GTPase KRAS interaction inhibitors reported to be useful for the treatment of cancer.

Jingrui Biopharma has described bromodomain and extra-terminal (BET) inhibitors, particularly bromodomain-containing protein 4 (BD1 domain) (Brd4 BD1) inhibitors, reported to be useful for the treatment of cancer.

Medshine Discovery has disclosed pyrazolopyrazine-linked tricyclic compounds acting as tyrosine-protein phosphatase non-receptor type 11 (PTPN11) inhibitors reported to be useful for the treatment of cancer.

MagicMed Industries has divulged new prenylated psilocybin derivatives acting as 5-HT2A and/or 5-HT1A receptor modulators reported to be useful for the treatment of psychiatric disorders.

Metabrain Research and Shanghai Visonpharma have presented macrocyclic Toll-like receptor 7 (TLR7) agonists reported to be useful for the treatment of hepatitis B virus (HBV), HCV, HIV and influenza virus infections, and cancer.

Allorion Therapeutics has divulged imidazolopyridazines or pyrazolopyrimidines acting as nonreceptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, Crohn's disease and systemic lupus erythematosus.

Beckley Psytech has synthesized new tryptamine analogues acting as 5-HT2A and/or 5-HT2B and/or 5-HT2C receptor agonists reported to be useful for the treatment of depression.

Reata Pharmaceuticals has described ursolic acid derivatives acting as nitric oxide (NO) production inhibitors and/or nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of cancer and inflammatory disorders, among other disorders.

E-Scape Bio has identified indazoles acting as leucine-rich repeat kinase 2 (LRRK2; dardarin) and/or LRRK2 (G2019S mutant) inhibitors reported to be useful for the treatment of Parkinson's dementia, multiple system atrophy, Lewy body dementia, Parkinson's disease and Alzheimer's disease.